3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
fludarabine phosphate
43
Whole-Body Irradiation
36
Mycophenolic Acid
36
Peripheral Blood Stem Cell Transplantation
31
Cyclophosphamide
31
Tacrolimus
28
Busulfan
22
Antilymphocyte Serum
21
Cyclosporine
19
fludarabine
17
ruxolitinib
16
Melphalan
16
Methotrexate
15
Cytarabine
12
thymoglobulin
9
Sirolimus
9
Etoposide
9
Granulocyte Colony-Stimulating Factor
8
Filgrastim
8
Cyclosporins
8
Radiotherapy
7
Cord Blood Stem Cell Transplantation
7
Rituximab
6
Alemtuzumab
6
merphos
5
Stem Cell Transplantation
5
Flow Cytometry
5
Azacitidine
5
sargramostim
4
ponatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Myeloproliferative Disorders
×
pertuzumab
×
Clear all
No trials found.